About: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Creator	Ren, Lili Wang, Jianwei Xiang, Zichun Chen, Ting Guo, Li Liu, Yan Chen, Xing Jin, Qi Lei, Xiaobo Qian, Zhaohui Li, Pei Mu, Zhixia Ou, Xiuyuan Mi, Dan Chen, Jieyong Guo, Ruixuan Hu, Jiaxin Hu, Keping
Source	Medline; PMC
abstract	Since 2002, beta coronaviruses (CoV) have caused three zoonotic outbreaks, SARS-CoV in 2002–2003, MERS-CoV in 2012, and the newly emerged SARS-CoV-2 in late 2019. However, little is currently known about the biology of SARS-CoV-2. Here, using SARS-CoV-2 S protein pseudovirus system, we confirm that human angiotensin converting enzyme 2 (hACE2) is the receptor for SARS-CoV-2, find that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, that PIKfyve, TPC2, and cathepsin L are critical for entry, and that SARS-CoV-2 S protein is less stable than SARS-CoV S. Polyclonal anti-SARS S1 antibodies T62 inhibit entry of SARS-CoV S but not SARS-CoV-2 S pseudovirions. Further studies using recovered SARS and COVID-19 patients’ sera show limited cross-neutralization, suggesting that recovery from one infection might not protect against the other. Our results present potential targets for development of drugs and vaccines for SARS-CoV-2.
has issue date	2020-03-27(xsd:dateTime)
bibo:doi	10.1038/s41467-020-15562-9
bibo:pmid	32221306
has license	no-cc
sha1sum (hex)	c5db08a4925ae08d69530ee3c2bb263f8fd9fca4
schema:url	https://doi.org/10.1038/s41467-020-15562-9
resource representing a document's title	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
has PubMed Central identifier	PMC7100515
has PubMed identifier	32221306
schema:publication	Nat Commun
resource representing a document's body	covid:c5db08a4925ae08d69530ee3c2bb263f8fd9fca4#body_text
is schema:about of	named entity 'They' named entity 'endocytosis' named entity 'infect' named entity 'remains' named entity 'causative' named entity 'analysis' named entity 'emerged' named entity 'glycoprotein' covid:arg/c5db08a4925ae08d69530ee3c2bb263f8fd9fca4 named entity 'severe' named entity 'outbreaks' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'protein' named entity 'MERS-CoV' named entity 'Yunnan' named entity 'vaccines' named entity 'nucleotide sequence' named entity 'SARS-CoV-2' named entity 'cave' named entity 'SARS-CoV-2' named entity 'stable' named entity 'sequenced' named entity 'virus' named entity 'SARS' named entity 'MERS-CoV' named entity 'neurological diseases' named entity 'China' named entity 'zoonotic' named entity 'zoonotic' named entity 'Bat' named entity 'SARS-CoV-2' named entity 'dromedary camel' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'SARS' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'SARS-CoV' named entity 'PIKfyve' named entity 'vaccines' named entity 'protein' named entity 'glycoprotein' named entity 'SARS-CoV-2' named entity 'enteric' named entity 'MERS-CoV' named entity 'virus' named entity 'transduce' named entity 'eGFP' named entity 'protein' named entity 'syncytia' named entity '3,5' named entity 'Addgene' named entity 'SARS-CoV-2' named entity 'protein' named entity 'syncytium' named entity 'apilimod' named entity 'HeLa' named entity 'MERS-CoV' named entity 'TPC2' named entity 'cytoplasmic' named entity 'SARS-CoV-2' named entity 'virus entry' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software